Bode M - Search Results

1

Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease.

Bode M, Diemer JN, Luu TV, Ehnert N, Teigeler T, Wiech T, Lindenmeyer MT, Herrnstadt GR, Bülow J, Huber TB, Tomas NM, Wenzel UO. Bode M, et al. Br J Pharmacol. 2023 Sep;180(18):2412-2435. doi: 10.1111/bph.16097. Epub 2023 May 18. Br J Pharmacol. 2023. PMID: 37076314 Free article.

2

A pathogenic role of complement in arterial hypertension and hypertensive end organ damage.

Wenzel UO, Bode M, Köhl J, Ehmke H. Wenzel UO, et al. Among authors: bode m. Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H349-H354. doi: 10.1152/ajpheart.00759.2016. Epub 2016 Dec 16. Am J Physiol Heart Circ Physiol. 2017. PMID: 27986662 Free article. Review.

3

Salt, inflammation, IL-17 and hypertension.

Wenzel UO, Bode M, Kurts C, Ehmke H. Wenzel UO, et al. Among authors: bode m. Br J Pharmacol. 2019 Jun;176(12):1853-1863. doi: 10.1111/bph.14359. Epub 2018 Jun 15. Br J Pharmacol. 2019. PMID: 29767465 Free PMC article. Review.

4

Adaptive immunity and IL-17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice.

Rosendahl A, Kabiri R, Bode M, Cai A, Klinge S, Ehmke H, Mittrücker HW, Wenzel UO. Rosendahl A, et al. Among authors: bode m. Br J Pharmacol. 2019 Jun;176(12):2002-2014. doi: 10.1111/bph.14509. Epub 2018 Dec 18. Br J Pharmacol. 2019. PMID: 30270435 Free PMC article.

5

B6.Rag1 Knockout Mice Generated at the Jackson Laboratory in 2009 Show a Robust Wild-Type Hypertensive Phenotype in Response to Ang II (Angiotensin II).

Seniuk A, Thiele JL, Stubbe A, Oser P, Rosendahl A, Bode M, Meyer-Schwesinger C, Wenzel UO, Ehmke H. Seniuk A, et al. Among authors: bode m. Hypertension. 2020 Apr;75(4):1110-1116. doi: 10.1161/HYPERTENSIONAHA.119.13773. Epub 2020 Feb 10. Hypertension. 2020. PMID: 32078412 Free article.

6

The role of complement in arterial hypertension and hypertensive end organ damage.

Wenzel UO, Kemper C, Bode M. Wenzel UO, et al. Among authors: bode m. Br J Pharmacol. 2021 Jul;178(14):2849-2862. doi: 10.1111/bph.15171. Epub 2020 Aug 19. Br J Pharmacol. 2021. PMID: 32585035 Free PMC article. Review.

7

Immune mechanisms in arterial hypertension. Recent advances.

Wenzel UO, Ehmke H, Bode M. Wenzel UO, et al. Among authors: bode m. Cell Tissue Res. 2021 Aug;385(2):393-404. doi: 10.1007/s00441-020-03409-0. Epub 2021 Jan 4. Cell Tissue Res. 2021. PMID: 33394136 Free PMC article. Review.

8

The role of the mineralocorticoid receptor in immune cells in cardiovascular disease.

van der Heijden CDCC, Bode M, Riksen NP, Wenzel UO. van der Heijden CDCC, et al. Among authors: bode m. Br J Pharmacol. 2022 Jul;179(13):3135-3151. doi: 10.1111/bph.15782. Epub 2022 Feb 15. Br J Pharmacol. 2022. PMID: 34935128 Free article. Review.

9

Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage.

Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R, Kappert K, Thiele A, Ritter D, Foryst-Ludwig A, Kolkhof P, Wenzel UO, Kintscher U. Luettges K, et al. Among authors: bode m. Am J Nephrol. 2022;53(7):552-564. doi: 10.1159/000524940. Epub 2022 Jun 8. Am J Nephrol. 2022. PMID: 35675794

10

Deficiency of Complement C3a and C5a receptors Does Not Prevent Angiotensin II-Induced Hypertension and Hypertensive End-Organ Damage.

Bode M, Herrnstadt GR, Dreher L, Ehnert N, Kirkerup P, Lindenmeyer MT, Meyer-Schwesinger CF, Ehmke H, Köhl J, Huber TB, Krebs CF, Steinmetz OM, Wiech T, Wenzel UO. Bode M, et al. Hypertension. 2024 Jan;81(1):138-150. doi: 10.1161/HYPERTENSIONAHA.123.21599. Epub 2023 Nov 1. Hypertension. 2024. PMID: 37909169 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

374 results

Search Page

Filters